TECHWIRE 30
(CIX: WRAL30)  910.15  down arrow-11.76  (-1.28 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NQ: Apple)  423.00  down arrow-8.77  (-2.03 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: Quintiles)  43.79  down arrow-0.1  (-0.23 %)  Updated: 04:15 PM EDT, Jun 19 2013
(OP: BASF SE)  97.15  down arrow-2.71  (-2.71 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NQ: BioCryst)  1.71  down arrow-0.08  (-4.47 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: BioDelivery)  4.53  down arrow-0.13  (-2.79 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: CEMP)  7.32  up arrow+0.19  (2.66 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Cisco Systems)  24.68  down arrow-0.14  (-0.56 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Cornerstone)  8.35  down arrow-0.1  (-1.18 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Cree)  65.05  down arrow-0.65  (-0.99 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: DARA)  0.67  down arrow-0.02  (-2.88 %)  Updated: 03:59 PM EDT, Jun 19 2013
(NY: EMC Corp.)  24.86  down arrow-0.13  (-0.52 %)  Updated: 04:15 PM EDT, Jun 19 2013
(NQ: Extreme Networks)  3.53  down arrow-0.02  (-0.56 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Facebook)  24.31  up arrow+0.1  (0.41 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: GlaxoSmithKline)  51.48  down arrow-0.99  (-1.89 %)  Updated: 04:15 PM EDT, Jun 19 2013
(NQ: Google)  900.68  up arrow+0.06  (0.01 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: IBM)  201.94  down arrow-2.93  (-1.43 %)  Updated: 04:15 PM EDT, Jun 19 2013
(NY: LH)  100.01  down arrow-0.77  (-0.76 %)  Updated: 04:15 PM EDT, Jun 19 2013
(OP: Lenovo Group)  18.70  down arrow-0.44  (-2.3 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NY: MRK)  47.58  down arrow-0.17  (-0.36 %)  Updated: 04:15 PM EDT, Jun 19 2013
(NQ: Microsoft Corp)  34.59  down arrow-0.39  (-1.11 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: NetApp)  38.98  down arrow-0.41  (-1.04 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: Novartis AG ADS)  71.90  down arrow-1.22  (-1.67 %)  Updated: 04:15 PM EDT, Jun 19 2013
(OP: Novozymes A/S)  34.00  down arrow-0.71  (-2.05 %)  Updated: 05:20 PM EDT, Jun 19 2013
(NY: Pfizer)  29.10  down arrow-0.3  (-1.02 %)  Updated: 04:15 PM EDT, Jun 19 2013
(NQ: Pozen)  4.96  down arrow-0.16  (-3.13 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NY: Red Hat)  46.22  down arrow-0.41  (-0.88 %)  Updated: 04:15 PM EDT, Jun 19 2013
(NQ: BBRY)  14.18  down arrow-0.66  (-4.44 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: Salix)  66.42  down arrow-0.41  (-0.61 %)  Updated: 04:00 PM EDT, Jun 19 2013
(NQ: SQI)  23.48  down arrow-0.1  (-0.42 %)  Updated: 04:00 PM EDT, Jun 19 2013

Posts tagged “Video game industry”

Updated October 13, 2008

Premium Lock BioDelivery Sciences promotes exec to chief technology spot

Niraj Vasisht is the new chief technical officer at BioDelivery Sciences International .

April 2, 2008

Premium Lock BioDelivery Sciences Receives $2.5 Million at Milestone

Meda AB Files for European Approval of BEMA™ Fentanyl

Updated January 15, 2008

Premium Lock BioDelivery Sciences to Expand Research for Breakthrough Pain Drug

BDSI Combination of narcotic, oral lozenge could be used to treat pain caused by other ailments beyond cancer.

Updated November 2, 2007

Premium Lock BioDelivery Sciences Moves HQ to Raleigh

BDSI Move to larger space made to accommodate more employees, company says.

Updated November 1, 2007

Premium Lock BioDelivery Sciences Files Application for Acute Pain Treatment

BDSI Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.

September 10, 2007

Premium Lock BioDelivery Sciences to Pay $7M for Ownership of Drug Delivery technology

BDSI RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.

Updated September 5, 2007

Premium Lock What a Relief: BDSI Lands $60M Deal for Rights to Cancer Pain Reliever

 Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.

Updated July 3, 2007

Premium Lock Application Process for Cancer Drug on Target

BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Jim Roberts
Entrepreneurship
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll

Videos

 
  • Allscripts bringing hundreds of jobs…

  • Nonprofit to handle NC economic…

  • Raleigh goes green, saves green with…

  • Gov. Pat McCrory speaks to NC Chamber

  • NC business leaders unveil job growth…

  • Investment expert: Leading is key in…

  • Retailers tout deals on Twitter

  • Vision for RTP: Social centerpiece